Health Trials

About this trial

Ablation of consecutive atrial tachycardia (AT) after ablation of atrial fibrillation (AF) or cardiac surgery can be challenging due to complex substrate and AT mechanisms. A substantial portion of patients is known to show various tachycardias and recurrences occur in a noticeable number of cases. With the availability of novel ultra-high-density mapping techniques characterization and understanding of AT mechanisms and underlying substrate can be improved. Aim of this prospective, multi-center, randomized study is to compare a standard AT ablation approach versus minimalized ablation of the clinical AT in regards to arrhythmia free survival.

Eligibility criteria

Qualifiers

Consecutive AT subsequent to prior AF ablation procedure or cardiac surgery

Surface ECG-documentation of AT as primary clinical arrhythmia

ECG indicating stable, map-able AT (stable activation sequence, and CL stability) with cycle length ≥ 200ms

Disqualifiers

< 18 years

No previous atrial fibrillation ablation procedure or cardiac surgery

Pregnant women or women of childbearing potential without a negative pregnancy test within 48 hours prior to treatment

History of hemorrhagic diathesis or other coagulopathies

Trial design

Treatments tested in this trial

  • Catheter ablation

Treatment groups

100 Participants
are divided into 2 treatment groups

Locations

6
Asklepios St. Georg HamburgFree and Hanseatic City of Hamburg, Germany
Evangelic Hospital Düsseldorf40217, DüsseldorfNorth Rhine-Westfalia, Germany
Vivantes Klinikum Am Urban Berlin Berlin Germany
Evangelic Hospital Hagen-Haspe Hagen Germany

Sponsors and collaborators

Evangelical Hospital Düsseldorf

Lead sponsor

Source ClinicalTrials.gov